Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency by Ballantyne, Laurel L. et al.
Molecular Genetics and Metabolism Reports 9 (2016) 54–60
Contents lists available at ScienceDirect
Molecular Genetics and Metabolism Reports
j ourna l homepage: www.e lsev ie r .com/ locate /ymgmrLiver-speciﬁc knockout of arginase-1 leads to a profound phenotype
similar to inducible whole body arginase-1 deﬁciencyLaurel L. Ballantyne a, Yuan Yan Sin a, Osama Y. Al-Dirbashi b,c, Xinzhi Li a, David J. Hurlbut d, Colin D. Funk a,⁎
a Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada
b Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada
c Faculty of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates
d Department of Pathology and Molecular Medicine, Queen's University, Kingston General Hospital, Kingston, ON, CanadaAbbreviations: Arg1, arginase-1; Arg1-eGFP, arginase
protein; AAV, adeno-associated virus; TBG, thyroxine-bin
ies; WT, wild-type; ip, intraperitoneal.
⁎ Corresponding author at: Department of Biomedical a
Street, Rm 433 Botterell Hall, Queen's University, Kingston
E-mail address: funkc@queensu.ca (C.D. Funk).
http://dx.doi.org/10.1016/j.ymgmr.2016.10.003
2214-4269/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 15 September 2016
Accepted 5 October 2016
Available online 12 October 2016Arginase-1 (Arg1) converts arginine to urea and ornithine in the distal step of the urea cycle in liver. We previ-
ously generated a tamoxifen-inducible Arg1 deﬁcient mouse model (Arg1-Cre) that disrupts Arg1 expression
throughout the whole body and leads to lethality≈2 weeks after gene disruption. Here, we evaluate if liver-
selective Arg1 loss is sufﬁcient to recapitulate the phenotype observed in global Arg1 knockout mice, as well as
to gauge the effectiveness of gene delivery or hepatocyte transplantation to rescue the phenotype. Liver-
selective Arg1 deletion was induced by using an adeno-associated viral (AAV)-thyroxine binding globulin
(TBG) promoter-Cre recombinase vector administered to Arg1 “ﬂoxed”mice; Arg1ﬂ/ﬂ). An AAV vector expressing
an Arg1-enhanced green ﬂuorescent protein (Arg1-eGFP) transgene was used for gene delivery, while
intrasplenic injection ofwild-type (WT) C57BL/6 hepatocytes after partial hepatectomywasused for cell delivery
to “rescue” tamoxifen-treated Arg1-Cre mice. The results indicate that liver-selective loss of Arg1 (N90% deﬁ-
cient) leads to a phenotype resembling the whole body knockout of Arg1 with lethality≈3 weeks after Cre-
induced gene disruption. Delivery of Arg1-eGFP AAV rescues more than half of Arg1 global knockout male
mice (survival N4 months) but a signiﬁcant proportion still succumb to the enzyme deﬁciency even though
liver expression and enzyme activity of the fusion protein reach levels observed in WT animals. Signiﬁcant
Arg1 enzyme activity from engrafted WT hepatocytes into knockout livers can be achieved but not sufﬁcient
for rescuing the lethal phenotype. This raises a conundrum relating to liver-speciﬁc expression of Arg1. On the
one hand, loss of expression in this organ appears to be both necessary and sufﬁcient to explain the lethal phe-
notype of the genetic disorder in mice. On the other hand, gene and cell-directed therapies suggest that rescue
of extra-hepatic Arg1 expression may also be necessary for disease correction. Further studies are needed in
order to illuminate the detailed mechanisms for pathogenesis of Arg1-deﬁciency.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In the urea cycle, arginase-1 (Arg1) catalyzes the distal step in the
conversion of ammonia to urea. Patients with the genetic disorder of
Arg1 deﬁciency display a unique phenotype relative to other urea
cycle disorders, consistingof hyperargininemia andneurological deﬁcits
including some or all of the features of spastic diplegia, seizures, intel-
lectual disability and failure to thrive [1,2]. Mouse models to study the
human disorder have been created and all recapitulate the main bio-
chemical feature of hyperargininemia [3–6]. However, the global Arg1-1 enhanced green ﬂuorescent
ding globulin; gc, genome cop-
ndMolecular Sciences, 18 Stuart
, ON K7L 3N6, Canada.
. This is an open access article underknockout (KO) exhibits a much more profound phenotype compared
to the human disorder with all mice dying approximately 2 weeks
after birth, presumably due to hyperammonemia [3]. To circumvent
the neonatal lethality, three groups have generated similar, but not
identical, inducible Arg1 KO mouse models with several differences
that have been described recently [1,4–6]. Thesemice also die invariably
2–3weeks after gene disruption. There are somedifferences in interpre-
tation of the mechanisms for lethality with contributing factors includ-
ing a wasting phenotype and also hyperammonemia [1].
We [7] and others [8–11] have focused on strategies to rescue the le-
thal phenotype of inducible and global Arg1 KO mouse models. Gene
therapeutic approaches work best but none have rescued every feature
of the genetic deﬁciency [7,9–11]. Understanding the mechanism(s) for
the pathological features of genetic Arg1 deﬁciency in order to develop
effective therapeutic strategies is paramount. An important question
that remains unresolved is if it is the loss of Arg1 expression in liver,
where Arg1 expression is by far the most abundant, that drives thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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spectively, or if it is due to the loss of extra-hepatic Arg1 expression
that is also contributing to the pathological sequelae.
Herein, we interrogate this question by generating liver-speciﬁc
Arg1 KO mice, in combination with various gene therapeutic efforts
and hepatocyte cell transplant rescue experiments. While we have not
yet determined speciﬁc mechanisms, we demonstrate that tissue-
speciﬁc Arg1 deﬁciency can be just as severe as global Arg1 absence
and have raised novel questions to be addressed in the ﬁeld of rare
urea cycle disorder research.
2. Materials and methods
2.1. Liver-speciﬁc Arg1 knockout mouse model
Arg1 ﬂoxed mice (Arg1ﬂ/ﬂ; N8 week old male) with loxP sites
ﬂanking exons 7 and 8 of the Arg1 gene [12] were injected with high
(1.5 × 1011 genome copies (gc)), medium (5 × 1010 gc) or low (1.5 ×
1010 gc) doses of an adeno-associated viral (AAV)-thyroxine binding
globulin (TBG) promoter-Cre recombinase vector (obtained from Uni-
versity of Pennsylvania Gene Therapy Core Services;
AAV8.TBG.PI.Cre.rBG) via the intraperitoneal (ip) route to induce liver-
speciﬁc Arg1 deﬁciency.
2.2. Global inducible Arg1 knockout mouse model
Arg1-Cre mice, originally obtained from the Jackson Laboratory and
bred in-house, derived from parental strains Arg1ﬂox (JAX 008817,
C57BL/6-Arg1tm1Pmu/J) and CreERT2 (JAX 008463, B6.129-
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) (male, 12–16 weeks old) were injected
ip on 5 sequential days with tamoxifen to induce global Arg1 deﬁciency
as previously described [4,7]. All procedures were reviewed and ap-
proved by the Queen's University Animal Care Committee (Funk
2011-048) and conformed to the Guidelines of the Canadian Council
on Animal Care. Unless otherwise speciﬁed, water and standard rodent
chow (containing 21.8% protein, 9% fat, 2.2% ﬁber, 5% minerals by
weight; PicoLab Mouse Diet 20 (5058)) were provided ad libitum. Spe-
ciﬁc signs of health deterioration due to arginase deﬁciency were pres-
ent in mice, regardless of gender, approximately 24–48 h before
exhibiting severe distress, which allowed for humane euthanization
byCO2 inhalation [4,7]. Humaneendpointswere deﬁned as bodyweight
loss of N15% relative to the weight at the time of the ﬁnal tamoxifen ad-
ministration, accompanied by a slightly hunched posture. Some mice
could lose substantial weight in a single daywhen approaching the end-
point resulting in some exceeding the 15% threshold.
2.3. Gene therapeutic delivery of Arg1-eGFP AAV vector
The AAVvector for transgene delivery has been previously described
[7]. Brieﬂy, the rh10 serotype vector expressing an Arg1-enhanced
green ﬂuorescent protein (Arg1-eGFP) transgene froma strong promot-
er (hybrid cytomegalovirus enhancer/chicken β-actin) was used in
male 8 weeks old Arg1-Cre mice at 1.5 × 1011 gc injected two weeks
prior to tamoxifen-induced Arg1 knockout to allow for adequate time
for transgene expression.
2.4. Two-thirds hepatectomy and intrasplenic injection of C57BL/6 wild-
type hepatocytes
Mice (female, N8 weeks old) were conditioned with retrorsine
(Sigma-Aldrich; 70 mg/kg ip, twice at 2 week intervals), a cell cycle in-
hibitor, to block proliferation of native hepatocytes [13]. Two-thirds
partial hepatectomy [14] was carried out 2 weeks after the last retror-
sine dose to create a selective growth advantage for transplanted WT
hepatocytes. Twomillion donor cells obtained from immunocompatible
female C57BL/6 mice were suspended in 0.1 ml of media (high glucoseDMEMsupplementedwith 15mMHEPES (pH7.4), 10% FBS and 100 nM
dexamethasone) and injected slowly over 20–30 s into the lower pole of
the spleen as described [13,14]. 15 weeks later, allowing sufﬁcient time
for donor cell engraftment, the usual tamoxifen-induced Arg1 knockout
procedure was carried out.
2.5. Biochemical measurements and Arg1 enzyme activity assay
Blood was collected from the submandibular vein. A 3.2 mm circle
from a dried blood spot sample collected on Whatman 903™ ﬁlter
paper card was punched into the designated well of a 96-well plate.
Sample preparation was based on the method described by Turgeon
et al. [15] with minor modiﬁcation. Brieﬂy, amino acids were extracted
using a methanolic solution containing the following isotope-labeled
amino acid internal standards: 15N,2-13C-glycine, d4-alanine, d8-
valine, d3-leucine, d3-methionine, 13C6-phenylalanine, 13C6-tyrosine,
d2-ornithine, d2-citrulline and 5-13C-d4-arginine-HCl (Cambridge Iso-
tope Laboratories). After evaporation under nitrogen, the residue was
derivatized using 3.0 N HCl in n-butanol at 60 °C for 20 min. Excess re-
agentwas evaporated to dryness using nitrogen followed by reconstitu-
tion with 80% acetonitrile. A 10 μl portion of sample was subjected to
analysis by mass spectrometry.
The analytical systemused in this study consisted of aWaters TQDe-
tector equipped with electrospray ionization (ESI) source, Waters
1525 μ Binary HPLC Pump and a Waters 2777C Sample Manager (Wa-
ters). Tandem mass spectrometric (MS/MS) analysis of amino acids
was achieved using a combination of selected reaction monitoring and
neutral loss of mass to charge (m/z) of 102 scans, with the ESI source
being operated in the positive ion mode.
Arg1 enzyme activity in liver homogenateswas assayed as described
previously [4,7]. One unit of activity is deﬁned as 10 nmol urea/μg
protein.
2.6. Western blot analysis
Liver tissues were homogenized in a solution containing T-PER solu-
tion and 1× HALT protease inhibitor cocktail (40 μl/mg tissue). Homog-
enates were further diluted in T-PER to a concentration of 1 mg/ml
protein with 2× Laemmli buffer. Protein samples (20–30 μg) were sub-
jected toWestern Blot analysis. Proteins separated by electrophoresis in
10% TGX FastCast acrylamide gels (Bio-Rad) were transferred to PVDF
membrane (Bio-Rad, TurboBlot system) and probed with rabbit poly-
clonal anti-Arg1 (C-terminal peptide; 1:10,000; Abcam #ab91279)
and mouse monoclonal anti-α-tubulin (1:5000; Sigma #T5168) anti-
bodies. Immunoreactive proteins were detected using HRP-conjugated
goat anti-rabbit or anti-mouse secondary antibody (1:7500; Sigma) en-
hanced chemiluminescence signal. Digitized images were recorded
with a FluorChem 8900 instrument (Alpha Innotech, San Leandro, CA).
Some images underwent semi-quantitation with publicly available
Image J software (Version 1.47, NIH).
2.7. Immunoﬂuorescence and pathological analysis of liver sections
Liver sections (6 μm)were deparafﬁnized and rehydrated with tolu-
ene and ethanol by routine procedures. Antigen retrieval was per-
formed by boiling slides in 10 mM citrate buffer, pH 6.0, 0.02% Tween-
20 (Arg1 staining) or Tris/EDTA buffer, pH 9.0, 0.05% Tween-20 (CD4
staining). After PBS rinsing, sections were permeabilized with 1×
PBS + 0.2% Triton X-100 for 10 min at room temperature then blocked
with 2% normal goat serum (Cedarlane) in PBS for 30–45 min. Sections
were incubated with rabbit polyclonal anti-Arg1 (1:100; Abcam
#ab91279), rabbit monoclonal (EPR19514) anti-CD4 (1:250; Abcam
#ab183685) in 1–2% goat serum, and mouse monoclonal anti-
glutamine synthetase (1:200; Abcam #ab64613) in serum, for 1 h at
room temperature or overnight at 4 °C. Secondary antibodies, goat
anti-rabbit IgG FITC (Arg1; Cedarlane), goat anti-rabbit IgG (H + L)
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anti-mouse IgG AlexaFluor 568 (GS; Life Technologies) were used.
Slides were then dehydrated, mounted with ProLong Gold antifade re-
agent with DAPI (Invitrogen), and stored at room temperature until
analysis. Visualization was performed with a ﬂuorescent microscope
(Leica, DM IRB, Richmond Hill, ON). Separate H&E sections, from both
the gene therapy and hepatocyte transplantation studies, were exam-
ined by a pathologist blinded as to the identity of the samples.
2.8. Statistical analysis
All results are expressed as mean ± standard error of mean (SEM).
Statistical analysis was performed using GraphPad Prism 6 (GraphPad
Software, San Diego, California, USA). Means were compared using the
two-tailed Student's t-test. P values of b0.05were considered statistical-
ly signiﬁcant.
3. Results
3.1. Liver-speciﬁc knockout of Arg1
Injection of AAV-TBG-Cre intoArg1 “ﬂoxed” (Arg1ﬂ/ﬂ)mice induced a
selective disruption of the Arg1 gene in liver as evidenced by PCR
genotyping of 11 separate tissues for the diagnostic band of 195 bp
(Arg1Δ allele indicative of loss of exons 7 and 8; Fig. 1A, lane 4).Western
blot analysis of liver protein extracts revealed a loss of 80–95% Arg1 in
the high- and mid-dose Cre-injected mice with almost no loss of Arg1
protein in 2 (of 3) low-dose Cre-injected mice (Fig. 1B and data not
shown). Arg1 enzymatic activity in the extracts correlated with Arg1
protein levels (Fig. 1C). Some residual Arg1 immunostaining could be
detected in discrete regions of liver sections in AAV-TBG-Cre low-dose
injected mice that retained some enzyme activity (Fig. 1D, left). This
staining was not co-localized with glutamine synthetase situated
around central veins. In contrast, Arg1 staining in liver sections from
WT mice was more widespread throughout the liver parenchyma
(Fig. 1D, right).1 2 7 83 4 5 9 10 116
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Fig. 1.AAV-TBG-Cre delivery results in loss of liver Arg1 expression. A. PCR genotyping of 11 tiss
heart; 3, lung; 4, liver; 5, kidney; 6, spleen; 7, small intestine; 8, esophagus; 9, tongue; 10, skele
1.2 kb bands represent the Arg1ﬂ allele. B. Western blot analysis of Arg1. Liver extracts from th
three mid-dose Cre-injected mice express almost no Arg1 protein. Tubulin is used as a loading
euthanized at day 21–22 post-injection (n = 7 high-, 6 mid-, 3 low-dose, respectively). None
at this time point and three in this group were not sacriﬁced nor assayed for enzymatic a
comparison on the right. D. Immunostaining for Arg1 (FITC, green) and glutamine synthetase
and a WT mouse (right panel).We compared the phenotype of the liver-speciﬁc Arg1 KOmicewith
that of whole-body Arg1 KOmice that we had previously generated [4,
7]. We observed a steady loss of body weight in the liver-speciﬁc Arg1
KO mice (high- and mid-dose Cre-injected) over the course of one
week,whichwas virtually identical towhatwehad observed previously
with global Arg1 KO mice that showed progressive loss of food intake/
appetite [4,7] (Fig. 2A). The designated humane endpoint in the mice
in these two groups (n= 13) was attained at day 21–22 post-Cre injec-
tion (Fig. 2B). Allmice in the low-dose groupwerewithout symptomsat
this time point. The only apparent difference between liver-speciﬁc KO
of Arg1 and global Arg1 loss was that the former mice survived approx-
imately 7–8 days longer (21 vs 13 days from the day of Cre-injection
and last tamoxifen dose to induce Cre-mediated deletion, respectively).
Concomitant with weight loss from 2 weeks to 3 weeks post high-
and mid-dosing with AAV-TBG-Cre, these liver-speciﬁc Arg1 KO mice
showed an elevation in blood arginine levels, which was not directly
correlated with the dose of AAV-TBG-Cre (Fig. 3).
3.2. Gene therapy to treat Arg1-deﬁcient mice
Since the liver-speciﬁc KO mice appeared to show the same pheno-
type as global Arg1 KOmice, we decided to extend our studies with the
latter group ofmice to improve outcomes using our gene therapy proto-
col delivery of an rh10 serotype AAV-Arg1-eGFP vector previously de-
scribed [7]. Here, we dosed male Arg1-Cre mice with this vector (n =
10) or an empty GFP-expressing vector (n = 3) two weeks prior to in-
ducing the knockoutwith tamoxifen to allow for adequate expression of
the transgene. All GFP vector-treated mice died at the usual time point
(13 days from the last dose of tamoxifen) with virtually no Arg1 liver
enzymatic activity (Fig. 4A, B). In contrast, only 2 of 10 mice, with low
Arg1 enzyme activity, died at this early time point in the AAV Arg1-
eGFP gene therapy group (Fig. 4A, B). The remaining 8mice all survived
long-term ≥3 months) and were euthanized at different time points for
a variety of reasons (Table 1). Six of the long-term survivors had liver
Arg1 enzymatic activity levels in the normal WT physiological range
(8–11 units in standard enzyme assay; Fig. 4A), while two were in the
supra-physiological range when euthanized. High expression of Arg1-WT a b c a b c
Tubulin
id-dose
Arg1
WT
B
std
low-dose mid-dosekDa
50
37
Arg1
GS
c
c
ues from a representativemouse injected with high-dose AAV-TBG-Cre. Lanes: 1, brain; 2,
tal muscle; 11, tail. The 195 bp band is diagnostic for the Arg1Δ allele, while the 252 bp and
ree low-dose Cre-injected mice express variable amounts of Arg1, whereas extracts from
control. C. Arg1 enzyme activity assay in the three groups of AAV-TBG-Cre-injected mice
of the low-dose Cre-injected mice (n = 6) displayed symptoms requiring euthanization
ctivity. Liver Arg1 enzymatic activity from a cohort of untreated animals is shown for
(Alexa Fluor 568, red) in liver sections from a low-dose Cre-injected mouse (left panel)
BA
Fig. 2. Liver-speciﬁc Arg1KO leads toweight loss and humane euthanization endpoint. A.Weight loss traces. B. Kaplan-Meier survival curves. Data for high- (n=7),mid- (n=6) and low-
dose (n = 6) AAV-TBG-Cre-injected mice are shown.
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chyma in these successfully-treated mice including adjacent to gluta-
mine synthetase-expressing cells (i.e. cell layer(s) surrounding central
veins) with two examples shown (Fig. 4C; mouse R10 after 3 months
of transgene expression and mouse R4 after 7 months).
Blood arginine levels at endpoint in the high-level Arg1-eGFP
transgene-expressing mice (137 ± 26 μM; range 64–242 μM; n = 8)
were not signiﬁcantly different from untreated WT C57BL/6 mice (107
and 117 μM; n = 2) or untreated Arg1ﬂ/ﬂ mice (see Fig. 3; n = 15)
and were signiﬁcantly less than in the eGFP transgene-treated mice
(807 ± 117 μM; n = 3, p b 0.001; see Table 1).
3.3. Hepatocyte transplantation to treat Arg1-deﬁcient mice
Wesought todeterminewhether transplantation of histocompatible
Arg1-expressing WT C57BL/6 hepatocytes could rescue the phenotype
of Arg1 deﬁciency. In pilot experiments, we tested various protocols
that would enhance the efﬁcacy of re-population of donor cells as
other groups had carried out with retrorsine, a cell cycle inhibitor, com-
bined with partial hepatectomy [14]. We selected two cycles of retror-
sine treatment followed by two-thirds liver removal and infusion of
2 × 106 donor cells into the spleen. Mice were then allowed to recover
for 15 weeks at which time tamoxifen-induced Arg1 gene disruption
was carried out. Non-retrorsine-treated mice with partial hepatectomyμ
Fig. 3. Blood arginine levels at two time points post-AAV-TBG-Cre injection (n=7high-, 6
mid-, 3 low-dose, respectively). Samples were analyzed from dried blood spots by mass
spectrometry as described in the Methods section. The two dotted lines represent
arginine levels in two cohorts of untreated Arg1ﬂ mice (n = 15 total) measured on two
separate occasions.lost body weight and had to be euthanized 15 days post-tamoxifen.
Mice in this group assayed for liver Arg1 activity displayed low enzyme
activity (Fig. 5A, B). Of the 9 retrorsine-treated mice, 5 displayed signif-
icantlymore enzymeactivity (N2 units) than typical Arg1 deﬁcientmice
(b1 unit) and lifespan was extended up to an extra week (day 20 post-
tamoxifen). Thesemice showed up to 5% re-population of liver Arg1 ex-
pression compared to WT controls as determined by immunostaining
(Fig. 5C). Large numbers of “islands” positive for staining were detected
throughout the regenerated liver parenchyma. After examination of
liver sections, it was determined that all hepatocyte-transplanted mice
showed normal lobular architecture with portal tracts and central
veins with no detected inﬂammatory cell inﬁltrates. Blood arginine
levels were signiﬁcantly elevated 14–20 days post-tamoxifen treatment
in the retrorsine-treated, repopulated recipient animals compared to
“baseline” levels shortly after tamoxifen treatment or to vehicle-
treated Arg1ﬂ/ﬂ mice (Fig. 5D).4. Discussion
The key ﬁndings of the present studies are: (i) liver-speciﬁc KO of
Arg1 in mice is lethal and leads to a phenotype that appears to be very
reminiscent to that of the induced global Arg1 KO mouse phenotype;
(ii) gene therapy with AAV vectors carrying an Arg1-eGFP expression
construct can correct the phenotype in most male mice but this is not
lifelong in duration; and (iii) syngeneic hepatocyte transplantation to
restore Arg1 expression in the induced Arg1 deﬁcientmousemodel, de-
spite radical steps to induce cell engraftment, remains a signiﬁcant
challenge.
The high- (1.5 × 1011 gc) and mid- (5 × 1010 gc) AAV-TBG-Cre dos-
ing regimens were very efﬁcient at producing liver-speciﬁc KO of Arg1
(N90%Arg1 protein loss; indistinguishable frombackground hepatocyte
Arg1 enzyme activity level in global induced Arg1 KO mouse model).
Liver-speciﬁc Arg1 KO mice appear to phenocopy the induced global
Arg1 KO mice in most respects, to the best of our knowledge. A major
biochemical factor in the tissue-speciﬁc KO is elevated blood arginine,
which translates into a wasting phenotype. We had previously hypoth-
esized how thismight occur [4,7] butwe are still lackingmechanistic in-
sight. Arginine is a central amino acid in the regulation of mammalian
cell physiology and can act as a sensor through various proteins to signal
via the mammalian target of rapamycin complex 1 (mTORC1) to regu-
late cell growth/autophagy/nutrient sensing/protein synthesis [16,17].
It is possible that thewastingphenotype in the tissue-speciﬁc and global
induced KOmodels is due to dysregulation of this pathway in the pres-
ence of elevated arginine levels. Blood ammonia levels rise after the
wasting phenotype has been irreversibly initiated and may contribute
to the very late-stages of demise of these mice [4,5,7].
R10
R4
A C
R10
R4
B
Fig. 4.AAV transgenedelivery of Arg1-eGFP restoresArg1 hepatic enzyme activity and prolongs lifespan relative to control eGFP-treatedmice. A. Arg1hepatic enzymatic activitymeasured
at endpoints in two groups (Arg1-eGFP treated, n = 10 and eGFP-treated, n = 3), as well as from a cohort of untreated animals (same as in Fig.1C) for comparison. B. Corresponding
Kaplan-Meier survival curves for two groups of mice. C. Immunostaining for Arg1 (FITC, green) and glutamine synthetase (Alexa Fluor 568, red) in liver sections from representative
mice; mouse R10 (euthanized after 3 months of transgene expression from unrelated skin lesions; top panel) and mouse R4 (euthanized after 7 months of transgene expression;
bottom panel). See Table 1 for details on individual mice.
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from pancreatic islet cells [18,19]. Moreover, injection of L-arginine at
high doses (2 × 4 g/kg 1 h apart), but not the D-enantiomer, into
C57BL/6mice evokes acute pancreatitis and subsequent pancreatic inju-
ry, which is followed by lung damage [20]. It is possible that
hyperargininemia in the liver-speciﬁc Arg1 KOmice is evoking pancre-
atic problems, which then affect feeding and metabolism.
Due to the complex and severe nature of the phenotype of Arg1 de-
ﬁciency in mice, it has been very challenging to rescue completely all
the features of the disorder. We have tried at least ﬁve different non-Table 1
Treatment of Arg1-cre mice with an AAV-delivered Arg1-eGFP transgene extends lifespan of m
# AAV
Vector
Time of
death
(days)a
Clinical characteristicsa
R1 Arg1-eGFP 330 Loss of BW; a few lobular inﬂammatory foci with CD4+ ly
R2 Arg1-eGFP 13 Loss of BW; mild portal and pericentral foci of mononucle
R3 Arg1-eGFP 210 Loss of BW; no inﬂammatory cells; no CD4+ staining
R4 Arg1-eGFP 210 Loss of BW; mild portal predominant foci of mononuclear
R5 eGFP 13 Loss of BW
R6 eGFP 13 Loss of BW; one single focus of mononuclear cells includi
R7 eGFP 13 Loss of BW; no CD4+ staining
R8 Arg1-eGFP 300 Bloody urine; undeﬁned tumor; no CD4+ staining
R9 Arg1-eGFP 13 Loss of BW; mild-moderate portal and periportal inﬂamm
R10 Arg1-eGFP 90 Skin lesions; no inﬂammation; no CD4+ staining
R11 Arg1-eGFP 365 Hepatocellular adenoma; focal mild-moderate macrovesi
R12 Arg1-eGFP 365 Moderate-severe macrovesicular steatosis; mild portal pr
cells; urinary tract blockage
R13 Arg1-eGFP 365 No overt problems; no inﬂammation; no CD4+ cells
a Time of death/euthanization is relative to the last tamoxifen dose. Mice were euthanized w
were on study for 1 year from the last tamoxifen dose. The clinical characteristics reported do n
mice and initiate hepatocellular carcinoma in a small number of hepatocytes, which leads to c
integration in this locus and not due to the expressed arginase transgene. Liver sections of mo
b Blood arginine [arg] levels were measured at endpoint. Two non-treated C57BL/6 controlgene therapy approaches, which were largely unsuccessful [7]. Others
[9,10] and our group [7] have had successes with AAV vector delivery
in the “juvenile” model and in the global induced Arg1 KO model, re-
spectively. Previously, in a study of 44 mice we showed partial rescue
of≈25% of male mice with no rescue of female mice using a rh10 sero-
type vector using a strong hybrid promoter [7]. Here, with 10 additional
male mice, we demonstrated an 80% “correction” that was sustained
over several months to a 1 year designated endpoint.We are not certain
as to why there was greater success here than in our previous study
since the same vector preparation was used for transgene deliveryice with tamoxifen-induced Cre-mediated Arg1 deﬁciency.
Blood
[arg]
(μM)b
mphocytes and Kupffer cells pericentral 121
ar inﬂammation; some CD4+ cells seen pericentrally 162
64
chronic inﬂammation including CD4+ cells 64
653
ng lymphocytes, plasma cells and Kupffer cells 1036
733
220
ation; minimal CD4+ staining 489
242
cular steatosis; no inﬂammation; no CD4+ cells 172
edominant foci of mononuclear chronic inﬂammation including CD4+ 88
126
hen humane endpoints relating to loss of body weight (BW) were reached or when mice
ot strictly identify exact cause of death. AAV integration can occur in the AAV-HCC locus of
lonal expansion [22]. The two tumors found in this study are likely consistent with vector
use R5 were not investigated.
mice at a comparable age (10 months) had levels of 107 and 117 μM.
WT
retrorsine-treated post-transplant
A DB
C
brightfield
Arg1
DAPI
μ
Fig. 5.WTArg1-expressinghepatocyte delivery onlymodestly extends lifespan of inducedArg1deﬁciencydespite signiﬁcant re-population of donor livers. A. Kaplan-Meier survival curves
of mice (n = 9, retrorsine-treated; n = 3, non-retrorsine-treated). B. Arg1 enzyme activity in livers of hepatocyte-repopulated mice at endpoint, as well as from a cohort of untreated
animals (same as in Fig.1C) for comparison. C. Arg1 immunostaining (FITC, green) in a liver section from a representative hepatocyte-transplanted Arg1-deﬁcient recipient mouse
15 weeks post-transplantation (middle panel) and 20 days post-tamoxifen-induced Arg1 knockout, along with corresponding low-magniﬁcation brightﬁeld image (left panel) and a
section from a non-treated C57BL/6 WT control mouse (right panel). D. Blood arginine levels at three time points post-tamoxifen (T) in retrorsine-treated mice. The two dotted lines
represent arginine levels in two cohorts of untreated Arg1ﬂ mice (n = 15 total) measured on two separate occasions, as in Fig.3.
59L.L. Ballantyne et al. / Molecular Genetics and Metabolism Reports 9 (2016) 54–60with only slightly varied “optimized” conditions. Arginase expression
seems to be widespread throughout the liver parenchyma early after
vector delivery in key cells carrying out urea cycle function and appar-
ently in most hepatic zones (both portal and central vein regions) but
appears to be lost in key portal circulation zones over time, presumably
due to hepatocyte regeneration in these zones, with consequent loss of
Arg1-transgene expression in these cells, which leads to loss of urea
cycle function and elevation of blood arginine. There was no clear cor-
relative indication of an immune response to either theAAV vector itself
or to the expressed transgenes (either Arg1-eGFP or eGFP alone) with
about half the mice showing inﬂammatory cell inﬁltrates early (day
13) and late (N3 months) and half showing no signs of CD4+ lympho-
cyte inﬁltration (see Table 1). eGFP is only minimally immunogenic in
C57BL/6 background mice [21].
In the hepatocyte transfer studies, we were unable to achieve sufﬁ-
cient, widespread expression of WT Arg1-expressing cells throughout
the liver when we induced Arg1 gene disruption with tamoxifen to res-
cue the knockout mice. Even though we created a selective growth ad-
vantage for the transplanted cells by partial hepatectomy and inhibition
of proliferation of native cells expressing Arg1 ﬂoxed alleles with retror-
sine, lifespan of the KOmicewas extended by only several days. Five (of
9) hepatocyte-transplanted mice displayed reasonable total hepatic
Arg1 expression (N15% of normal liver Arg1 enzyme activity), which
we surmise should be sufﬁcient to maintain essential urea cycle func-
tion. Thus, we can think of two scenarios as to why the mice are still
not “rescued”: (i) the transplanted cells that migrated to the liver after
intrasplenic injection did not fully recapitulate thenormal liver distribu-
tion of arginase and thus there is not sufﬁcient Arg1 enzyme in the cor-
rect metabolic zones; (ii) that extra-hepatic Arg1 activity is also
necessary for full “rescue” in this particular mousemodel. This certainly
raises more questions than answers. On the one hand, loss of liver argi-
nase expression appears to be both necessary and sufﬁcient to explain
the lethal phenotype of the genetic disorder in mice. On the other
hand, gene and cell-directed therapies are pointing towards the notionthat rescue of extra-hepatic Arg1 expression may also be necessary for
disease correction.
Signiﬁcant challenges lie ahead to rescue the lethal phenotype of
global induced Arg1 or liver-selective Arg1 deﬁciency in mice.
Acknowledgements
CDF is supported by the Canada Research Chairs program and the
Canadian Institutes of Health Research (CIHR) (MOP-341036). We ac-
knowledge the University of Pennsylvania Penn Vector Core Gene Ther-
apy Program for production and supply of the AAV vectors used in this
study.
References
[1] Y.Y. Sin, G. Baron, A. Schulze, C.D. Funk, Arginase-1 deﬁciency, J. Mol. Med. 93 (2015)
1287–1296.
[2] R. Iyer, C.P. Jenkinson, J.G. Vockley, R.M. Kern, W.W. Grody, S. Cederbaum, The
human arginases and arginase deﬁciency, J. Inherit. Metab. Dis. 21 (Suppl 1)
(1998) 86–100.
[3] R.K. Iyer, P.K. Yoo, R.M. Kern, N. Rozengurt, R. Tsoa, W.E. O'Brien, et al., Mouse model
for human arginase deﬁciency, Mol. Cell. Biol. 22 (2002) 4491–4498.
[4] Y.Y. Sin, L.L. Ballantyne, K. Mukherjee, T. St Amand, L. Kyriakopoulou, A. Schulze,
et al., Inducible arginase 1 deﬁciency in mice leads to hyperargininemia and altered
amino acid metabolism, PLoS One 8 (11) (2013), e80001.
[5] J. Kasten, C. Hu, R. Bhargava, H. Park, D. Tai, J.A. Byrne, et al., Lethal phenotype in con-
ditional late-onset arginase 1 deﬁciency in the mouse, Mol. Genet. Metab. 110
(2013) 222–230.
[6] L.C. Burrage, Q. Sun, S.H. Elsea, M.M. Jiang, S.C. Nagamani, A.E. Frankel, E. Stone, S.E.
Alters, D.E. Johnson, S.W. Rowlinson, G. Georgiou, Members of Urea Cycle Disorders
Consortium, B.H. Lee, Human recombinant arginase enzyme reduces plasma argi-
nine in mouse models of arginase deﬁciency, Hum. Mol. Genet. 24 (2015)
6417–6427.
[7] L.L. Ballantyne, Y.Y. Sin, T. St Amand, J. Si, S. Goossens, L. Haenebalcke, J.J. Haigh, L.
Kyriakopoulou, A. Schulze, C.D. Funk, Strategies to rescue the consequences of in-
ducible arginase-1 deﬁciency in mice, PLoS One 10 (5) (2015), e0125967.
[8] C.L. Gau, R.A. Rosenblatt, V. Cerullo, F.D. Lay, A.C. Dow, J. Livesay, et al., Short-term
correction of arginase deﬁciency in a neonatal murine model with a helper-
dependent adenoviral vector, Mol. Ther. 17 (2009) 1155–1163.
60 L.L. Ballantyne et al. / Molecular Genetics and Metabolism Reports 9 (2016) 54–60[9] E.K. Lee, C. Hu, R. Bhargava, N. Rozengurt, D. Stout, W.W. Grody, et al., Long-term
survival of the juvenile lethal arginase-deﬁcient mouse with AAV gene therapy,
Mol. Ther. 20 (2012) 1844–1851.
[10] E.K. Lee, C. Hu, R. Bhargava, R. Ponnusamy, H. Park, S. Novicoff, et al., AAV-based
gene therapy prevents neuropathology and results in normal cognitive develop-
ment in the hyperargininemic mouse, Gene Ther. 20 (2013) 785–796.
[11] C. Hu, J. Kasten, H. Park, R. Bhargava, D.S. Tai, W.W. Grody, et al., Myocyte-mediated
arginase expression controls hyperargininemia but not hyperammonemia in
arginase-deﬁcient mice, Mol. Ther. 22 (2014) 1792–1802.
[12] K.C. El Kasmi, J.E. Qualls, J.T. Pesce, A.M. Smith, R.W. Thompson, M. Henao-Tamayo,
et al., Toll-like receptor-induced arginase 1 inmacrophages thwarts effective immu-
nity against intracellular pathogens, Nat. Immunol. 9 (2008) 1399–1406.
[13] D. Guo, T. Fu, J.A. Nelson, R.A. Superina, H.E. Soriano, Liver repopulation after cell
transplantation inmice treated with retrorsine and carbon tetrachloride, Transplan-
tation 73 (2002) 1818–1824.
[14] C. Mitchell, H.Willenbring, A reproducible and well-toleratedmethod for 2/3 partial
hepatectomy inmice, Nat. Protoc. 3 (2008) 1167–1170 (and addendum: Nat Protoc.
2014; 9).
[15] C. Turgeon, M.J. Magera, P. Allard, S. Tortorelli, D. Gavrilov, D. Oglesbee, K. Raymond,
P. Rinaldo, D. Matern, Combined newborn screening for succinylacetone, amino
acids, and acylcarnitines in dried blood spots, Clin. Chem. 54 (2008) 657–664.[16] L. Chantranupong, S.M. Scaria, R.A. Saxton, M.P. Gygi, K. Shen, G.A. Wyant, T. Wang,
J.W. Harper, S.P. Gygi, D.M. Sabatini, The CASTOR proteins are arginine sensors for
the mTORC1 pathway, Cell 165 (2016) 153–164.
[17] V.P. Tan, S. Miyamoto, Nutrient-sensing mTORC1: Integration of metabolic and au-
tophagic signals, J. Mol. Cell. Cardiol. (2016 Jan 7) (pii: S0022-2828(16)30002-5).
[18] J.P. Palmer, J.W. Benson, R.M. Walter, J.W. Ensinck, Arginine-stimulated acute phase
of insulin and glucagon secretion in diabetic subjects, J. Clin. Invest. 58 (1976)
565–570.
[19] P. Thams, K. Capito, L-arginine stimulation of glucose-induced insulin secretion
through membrane depolarization and independent of nitric oxide, Eur. J.
Endocrinol. 140 (1999) 87–93.
[20] R. Dawra, R. Sharif, P. Phillips, V. Dudeja, D. Dhaulakhandi, A.K. Saluja, Development
of a newmousemodel of acute pancreatitis induced by administration of L-arginine,
Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G1009–G1018.
[21] D. Skelton, N. Satake, D.B. Kohn, The enhanced green ﬂuorescent protein (eGFP) is
minimally immunogenic in C57BL/6 mice, Gene Ther. 8 (2001) 1813–1814.
[22] D.W. Russell, AAV vectors, insertional mutagenesis, and cancer, Mol. Ther. 15 (2007)
1740–1743.
